169 related articles for article (PubMed ID: 19387354)
1. Prevalence and persistence of cervical human papillomavirus infection in HIV-positive women initiating highly active antiretroviral therapy.
Fife KH; Wu JW; Squires KE; Watts DH; Andersen JW; Brown DR
J Acquir Immune Defic Syndr; 2009 Jul; 51(3):274-82. PubMed ID: 19387354
[TBL] [Abstract][Full Text] [Related]
2. Association of HIV viral load and CD4 cell count with human papillomavirus detection and clearance in HIV-infected women initiating highly active antiretroviral therapy.
Kang M; Cu-Uvin S
HIV Med; 2012 Jul; 13(6):372-8. PubMed ID: 22257000
[TBL] [Abstract][Full Text] [Related]
3. The impact of highly active antiretroviral therapy on prevalence and incidence of cervical human papillomavirus infections in HIV-positive adolescents.
Shrestha S; Sudenga SL; Smith JS; Bachmann LH; Wilson CM; Kempf MC
BMC Infect Dis; 2010 Oct; 10():295. PubMed ID: 20946655
[TBL] [Abstract][Full Text] [Related]
4. Human papillomavirus prevalence, viral load and pre-cancerous lesions of the cervix in women initiating highly active antiretroviral therapy in South Africa: a cross-sectional study.
Moodley JR; Constant D; Hoffman M; Salimo A; Allan B; Rybicki E; Hitzeroth I; Williamson AL
BMC Cancer; 2009 Aug; 9():275. PubMed ID: 19664216
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of HIV and highly active antiretroviral therapy on the natural history of human papillomavirus infection and cervical cytopathologic findings in HIV-positive and high-risk HIV-negative women.
Blitz S; Baxter J; Raboud J; Walmsley S; Rachlis A; Smaill F; Ferenczy A; Coutlée F; Hankins C; Money D;
J Infect Dis; 2013 Aug; 208(3):454-62. PubMed ID: 23624362
[TBL] [Abstract][Full Text] [Related]
6. Influence of HIV-1 and/or HIV-2 infection and CD4 count on cervical HPV DNA detection in women from Senegal, West Africa.
Hanisch RA; Sow PS; Toure M; Dem A; Dembele B; Toure P; Winer RL; Hughes JP; Gottlieb GS; Feng Q; Kiviat NB; Hawes SE;
J Clin Virol; 2013 Dec; 58(4):696-702. PubMed ID: 24210330
[TBL] [Abstract][Full Text] [Related]
7. Human papilloma virus types in the oral and cervical mucosa of HIV-positive South African women prior to antiretroviral therapy.
Richter KL; van Rensburg EJ; van Heerden WF; Boy SC
J Oral Pathol Med; 2008 Oct; 37(9):555-9. PubMed ID: 18355174
[TBL] [Abstract][Full Text] [Related]
8. HIV-1 seroconversion promotes rapid changes in cervical human papillomavirus (HPV) prevalence and HPV-16 antibodies in female sex workers.
Marais DJ; Carrara H; Ramjee G; Kay P; Williamson AL
J Med Virol; 2009 Feb; 81(2):203-10. PubMed ID: 19107974
[TBL] [Abstract][Full Text] [Related]
9. Associations between highly active antiretroviral therapy and the presence of HPV, premalignant and malignant cervical lesions in sub-Saharan Africa, a systematic review: current evidence and directions for future research.
Menon S; Rossi R; Zdraveska N; Kariisa M; Acharya SD; Vanden Broeck D; Callens S
BMJ Open; 2017 Aug; 7(8):e015123. PubMed ID: 28780541
[TBL] [Abstract][Full Text] [Related]
10. High risk human papillomavirus prevalence and genotype distribution among women infected with HIV in Manaus, Amazonas.
Teixeira MF; Sabidó M; Leturiondo AL; de Oliveira Ferreira C; Torres KL; Benzaken AS
Virol J; 2018 Feb; 15(1):36. PubMed ID: 29454382
[TBL] [Abstract][Full Text] [Related]
11. Human papillomavirus detection in women with and without human immunodeficiency virus infection in Colombia.
Camargo M; Soto-De Leon SC; Munoz M; Sanchez R; Peña-Herrera D; Pineda-Peña AC; Sussmann O; Paez C; Perez-Prados A; Patarroyo ME; Patarroyo MA
BMC Cancer; 2014 Jun; 14():451. PubMed ID: 24942545
[TBL] [Abstract][Full Text] [Related]
12. Sustained viral suppression and higher CD4+ T-cell count reduces the risk of persistent cervical high-risk human papillomavirus infection in HIV-positive women.
Konopnicki D; Manigart Y; Gilles C; Barlow P; de Marchin J; Feoli F; Larsimont D; Delforge M; De Wit S; Clumeck N
J Infect Dis; 2013 Jun; 207(11):1723-9. PubMed ID: 23463709
[TBL] [Abstract][Full Text] [Related]
13. Human papillomavirus in women infected with human immunodeficiency virus: association with viral load and lymphocyte count.
Morais ACCD; Ferreira AS; Barbosa CDT; Lima MFB; Fook KD; Carvalho MM; Muniz ACS; Araújo DR; Monteiro PM; Araújo MJAM; Monteiro SCM; Lopes FF
Rev Inst Med Trop Sao Paulo; 2024; 66():e36. PubMed ID: 38865574
[TBL] [Abstract][Full Text] [Related]
14. Prevalence of and Risk Factors for Anal Oncogenic Human Papillomavirus Infection Among HIV-Infected Women in France in the Combination Antiretroviral Therapy Era.
Heard I; Poizot-Martin I; Potard V; Etienney I; Crenn-Hebert C; Moore C; Touraine P; Cubie H; Costagliola D;
J Infect Dis; 2016 May; 213(9):1455-61. PubMed ID: 26690345
[TBL] [Abstract][Full Text] [Related]
15. Transitional probability-based model for HPV clearance in HIV-1-positive adolescent females.
Kravchenko J; Akushevich I; Sudenga SL; Wilson CM; Levitan EB; Shrestha S
PLoS One; 2012; 7(1):e30736. PubMed ID: 22292027
[TBL] [Abstract][Full Text] [Related]
16. Combination antiretroviral therapy reduces the detection risk of cervical human papilloma virus infection in women living with HIV.
Zeier MD; Botha MH; Engelbrecht S; Machekano RN; Jacobs GB; Isaacs S; van Schalkwyk M; van der Merwe H; Mason D; Nachega JB
AIDS; 2015 Jan; 29(1):59-66. PubMed ID: 25387313
[TBL] [Abstract][Full Text] [Related]
17. Human papillomavirus infection and associated cervical disease in human immunodeficiency virus-infected women: effect of highly active antiretroviral therapy.
Lillo FB; Ferrari D; Veglia F; Origoni M; Grasso MA; Lodini S; Mastrorilli E; Taccagni G; Lazzarin A; Uberti-Foppa C
J Infect Dis; 2001 Sep; 184(5):547-51. PubMed ID: 11494160
[TBL] [Abstract][Full Text] [Related]
18. HIV-1, HIV-2, human papillomavirus infection and cervical neoplasia in high-risk African women.
Langley CL; Benga-De E; Critchlow CW; Ndoye I; Mbengue-Ly MD; Kuypers J; Woto-Gaye G; Mboup S; Bergeron C; Holmes KK; Kiviat NB
AIDS; 1996 Apr; 10(4):413-7. PubMed ID: 8728046
[TBL] [Abstract][Full Text] [Related]
19. High-risk human papillomavirus reactivation in human immunodeficiency virus-infected women: risk factors for cervical viral shedding.
Theiler RN; Farr SL; Karon JM; Paramsothy P; Viscidi R; Duerr A; Cu-Uvin S; Sobel J; Shah K; Klein RS; Jamieson DJ
Obstet Gynecol; 2010 Jun; 115(6):1150-1158. PubMed ID: 20502284
[TBL] [Abstract][Full Text] [Related]
20. Human Papillomavirus Serology Among Women Living With HIV: Type-Specific Seroprevalence, Seroconversion, and Risk of Cervical Reinfection.
Kelly H; Faust H; Chikandiwa A; Ngou J; Weiss HA; Segondy M; Dillner J; Delany-Moretlwe S; Mayaud P
J Infect Dis; 2018 Aug; 218(6):927-936. PubMed ID: 29850832
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
